Bristol-Myers Squibb Company (BMY)

pos +0.00
Today's Range: 54.08 - 54.72 | BMY Avg Daily Volume: 12,102,800
Last Update: 02/17/17 - 4:00 PM EST
Volume: 0
YTD Performance: -6.59%
Open: $0.00
Previous Close: $54.28
52 Week Range: $46.01 - $77.12
Oustanding Shares: 1,671,229,946
Market Cap: 90,714,361,469
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 7 6 6
Moderate Buy 1 1 1 0
Hold 7 7 9 10
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.35 2.35 2.50 2.56
Latest Dividend: 0.39
Latest Dividend Yield: 2.87%
Dividend Ex-Date: 01/04/17
Price Earnings Ratio: 20.48
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
20.48 20.50 30.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.69% -14.60% 0.40%
Revenue 4.30 0.20 0.06
Net Income 166.70 0.80 0.20
EPS 174.00 0.70 0.19
Earnings for BMY:
Revenue 19.43B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $0.73 $0.69 $2.80 $3.07
Number of Analysts 5 5 11 9
High Estimate $0.78 $0.72 $2.90 $3.60
Low Estimate $0.69 $0.66 $2.69 $2.64
Prior Year $0.74 $0.69 $2.83 $2.80
Growth Rate (Year over Year) -0.81% -0.58% -1.16% 9.67%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.
You might want to review your holdings in the sector.

Takeaways and Observations Real Money Pro($)

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters. 

Biotech Buoyed by Deal Talk Real Money Pro($)

M&A activity is in a serious upswing, and here are some names to watch.
Two industries should largely be avoided under this administration: pharma and retail.
M&A, drug approvals and Trump are all on my watch list.
Jan 30, 2017 | 6:58 AM EST
Shares of BMY now seen reaching $52, according to Credit Suisse. Estimates also reduced, given the latest update on an Opdivo combinati...
Jan 27, 2017 | 6:46 AM EST
Shares of BMY now seen reaching $60, according to Jefferies. Estimates also reduced, given the company's new guidance. Buy rating.

My Takeaways and Observations Real Money Pro($)

The U.S. Dollar strengthened. The price of crude oil rose by over one dollar to $53.78/barrel. Gold fell by -$8.60 to $1189. Ag commodities: wheat +2.50, corn -2.50, soybean -7 and oats -5.5. Lumber increased by $1.50. Bonds rallied in price after an early morning spill. Yields dropped by two basis points. The yield curve was flat. Municipal bonds were flat, as were closed end muni bond funds. Junk was unchanged, Blackstone/GSO Strategic Credit Fund (BGB)  down $0.03. Banks prospered, though Citigroup (C) was lower. Insurance was mixed after a Metlife (MET) downgrade. Brokerages solid, led by GS (short and on Best Ideas List). Big pharma continues out of favor after large downside at Bristol-Myers (BMY) . Johnson & Johnson (JNJ) continues weak, after M&A announcement. Retail continues to underperform and the possible 20% tariff from Mexico (that Sean Spicer just mentioned) won't help. Nor will the possibility of a Sears (SHLD) bankruptcy (plenty of discounted merchandise could cause some indigestion over the next few months. Old media was mixed, awaiting Microsoft (MSFT) EPS this afternoon. Biotech continued its fade led by Allergan (AGN) , Celgene (CELG) and Gilead Sciences (GILD) . Speculative biotech also got hit. Consumer staples faltered despite the currency weakness. Campbell Soup (CPB) and Procter &


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.